BACKGROUND: The proposed definition of a partial virological response (PVR) to nucleos(t)ide analogue therapy in the 2009 European Association for the Study of the Liver (EASL) guidelines is based on limited evidence, especially in terms of the cutoff HBV DNA level and the time point at which to judge it. This study assessed optimal PVR criteria for predicting virological response (VR) at week 96 in treatment-naive patients with chronic hepatitis B (CHB) receiving entecavir (ETV). METHODS: A total of 175 patients (126 men, 49 women) who completed 96 weeks of first-line ETV therapy were prospectively recruited. For predicting VR at week 96, the area under the receiver operating characteristic curve (AUC) was used to find the optimal time point and the Youden index was used to calculate the optimal cutoff HBV DNA level. RESULTS: After 96 weeks of ETV therapy, 139 (79.4%) patients achieved VR. The AUC at week 48 was significantly better than that at week 24 for predicting VR at week 96 (P=0.023). The optimal cutoff HBV DNA level at week 48 was 35 IU/ml. Forty-one (23.4%) patients met this PVR criteria of ETV (HBV DNA level >35 IU/ml at week 48). CONCLUSIONS: An HBV DNA level >35 IU/ml at week 48 is the optimal PVR criteria for predicting non-VR at week 96 in treatment-naive patients with CHB who are receiving ETV. This study supports the proposed EASL PVR for ETV based on scientific evidence.
BACKGROUND: The proposed definition of a partial virological response (PVR) to nucleos(t)ide analogue therapy in the 2009 European Association for the Study of the Liver (EASL) guidelines is based on limited evidence, especially in terms of the cutoff HBV DNA level and the time point at which to judge it. This study assessed optimal PVR criteria for predicting virological response (VR) at week 96 in treatment-naive patients with chronic hepatitis B (CHB) receiving entecavir (ETV). METHODS: A total of 175 patients (126 men, 49 women) who completed 96 weeks of first-line ETV therapy were prospectively recruited. For predicting VR at week 96, the area under the receiver operating characteristic curve (AUC) was used to find the optimal time point and the Youden index was used to calculate the optimal cutoff HBV DNA level. RESULTS: After 96 weeks of ETV therapy, 139 (79.4%) patients achieved VR. The AUC at week 48 was significantly better than that at week 24 for predicting VR at week 96 (P=0.023). The optimal cutoff HBV DNA level at week 48 was 35 IU/ml. Forty-one (23.4%) patients met this PVR criteria of ETV (HBV DNA level >35 IU/ml at week 48). CONCLUSIONS: An HBV DNA level >35 IU/ml at week 48 is the optimal PVR criteria for predicting non-VR at week 96 in treatment-naive patients with CHB who are receiving ETV. This study supports the proposed EASL PVR for ETV based on scientific evidence.
Authors: Hana Park; Jun Yong Park; Seung Up Kim; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn Journal: World J Gastroenterol Date: 2013 Impact factor: 5.742
Authors: Mi Sung Park; Beom Kyung Kim; Kyung Sik Kim; Ja Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Oidov Baartarkhuu; Kwang Hyub Han; Chae Yoon Chon; Sang Hoon Ahn Journal: Clin Mol Hepatol Date: 2013-03-25
Authors: Dae Won Jun; Byung Ik Kim; Yong Kyun Cho; Hong Ju Kim; Young Oh Kwon; Soo Young Park; Sang Young Han; Yang Hyun Baek; Yong Jin Jung; Hwi Young Kim; Won Kim; Jeong Heo; Hyun Young Woo; Seong Gyu Hwang; Kyu Sung Rim; Jong Young Choi; Si Hyun Bae; Young Sang Lee; Young Suck Lim; Jae Youn Cheong; Sung Won Cho; Byung Seok Lee; Seok Hyun Kim; Joo Hyun Sohn; Tae Yeob Kim; Yong Han Paik; Ja Kyung Kim; Kwan Sik Lee Journal: Clin Mol Hepatol Date: 2013-06-27
Authors: Joon Chang Song; Bo Young Min; Jin Wook Kim; Jong Yeop Kim; Yeo Myeong Kim; Cheol Min Shin; Sang Hyub Lee; Jin Hyeok Hwang; Sook Hyang Jeong; Nayoung Kim; Dong Ho Lee Journal: Korean J Hepatol Date: 2011-12
Authors: Dae Hun Kwon; In Hee Kim; Bum Su Choung; Dae Seon Ahn; Sun Ho Yoo; Sang Bae Park; Seok Lee; Seong Hun Kim; Sang Wook Kim; Yong Jin Im Journal: Gut Liver Date: 2013-08-14 Impact factor: 4.519